Abstract: FIGS. 1-16D & 66A-92D disclose a large variety of methods of forming the headgear for use in combination with a breathing apparatus including a unitary plastic core within textile casings. In some configurations, the plastic core material penetrates or bursts-through the textile casing of the straps. Some configurations include over moulding, alignment posts, T-joints and joint housings with injection aperture. FIGS. 17-65 & 93A-94C disclose a large variety of different headgear arrangements including top strap, front strap, rear strap and pairs of straps extending from the mask above and below the ear to meet behind the ear. FIGS. 95-121B disclose a large variety of connectors connecting the headgear assembly to the mask assembly where the headgear, mask and connector form a closed loop when the connector is disengaged with the mask assembly.

Abstract: Aspects of the present disclosure relate to systems and methods for detecting emerging events. In various examples, a method for detecting emerging events includes obtaining communication data associated with communication between multiple sources, segmenting communication data into multiple segments, determining whether a data segment belongs to a familiar topic or none, and generating a notification when a familiar topic is mentioned for more or less than a mention prediction. Additionally, or alternatively, a notification may be generated when an unfamiliar topic emerges from a set of unfamiliar data segments if an associated segment count exceeds a critical mass threshold. To determine whether a data segment belongs to a familiar topic, the data segment may be transformed into a feature vector and mapped onto a feature space, where a distance-based similarity score may be determined.

Abstract: Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or integrins. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, inflammatory bowel syndrome, non-alcoholic fatty liver disease, and nonalcoholic steatohepatitis.

Abstract: Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.

Abstract: Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.

Abstract: Disclosed herein are antibodies that specifically bind to LRIG1 and methods of use thereof. In some embodiments, also described herein are methods of modulating immune system activity or promoting immune cell proliferation with an antibody that specifically binds to LRIG1.

Abstract: Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.

Abstract: Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.

Abstract: Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.

Abstract: Provided herein are methods and compositions for activating an immune response in a patient hosting a tumor. In some instances, a method described herein comprises administering to the patient a non-glycosylated PD-1 inhibitor and optionally a glycosylated PD-1 inhibitor, in which the non-glycosylated PD-1 inhibitor and optionally in combination with a glycosylated PD-1 inhibitor results in activation of the immune response.

Abstract: Disclosed herein are antibodies that specifically bind to LRIG1 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting B cell or Natural Killer cell proliferation with an antibody that specifically binds to LRIG1.

Abstract: A set of human torso manikins for use in fabrication and evaluation of body wear for a group of human beings, the torso manikins being shaped and dimensioned to conform to selected parameters derived from statistical analysis of the group. The manikins include a central human torso manikin of a shape corresponding to a multivariate center of anthropometric distributions of selected members of the group, and a plurality of extreme human torso form manikins each of a shape corresponding to a multivariate extreme suitable for accommodation of 90% of the group. About half of the plurality of extreme human torso form manikins exhibits a dimensional specification substantially less than a corresponding specification of the central human torso manikin and about another half of the plurality of extreme human torso form manikins exhibits a dimensional specification substantially greater than the corresponding specification of the central human torso manikin.